ARCHIVES

Officals: “Separations” in Normal Range as Critics Claim Brain Drain in the Clinic

This article is from The Cancer Letter archive.

Vol. 40 No. 03 | January 17, 2014

Download PDF Visit The Full Archive

Related Articles

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

April 25, 2014

Insurance Co. Official Says Cancer Centers, Insurers Are “Allies”

June 2, 1995

Study: Ibrutinib Lowers IgM, Bone Marrow Disease Burden

July 26, 2013

Funding opportunities listed.

October 29, 2004

Review Planned Of 54 Deaths In First 60 Days On Studies.

June 22, 2001

NCI CTEP-Approved Trials For the Month of June

June 27, 2014